A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine

Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Albayrak, Yakup, Beyazyüz, Murat, Abbak, Özlem, Altındağ, Ece
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361034/
https://www.ncbi.nlm.nih.gov/pubmed/30690950
http://dx.doi.org/10.9758/cpn.2019.17.1.134
_version_ 1783392632870797312
author Albayrak, Yakup
Beyazyüz, Murat
Abbak, Özlem
Altındağ, Ece
author_facet Albayrak, Yakup
Beyazyüz, Murat
Abbak, Özlem
Altındağ, Ece
author_sort Albayrak, Yakup
collection PubMed
description Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin reuptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders.
format Online
Article
Text
id pubmed-6361034
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-63610342019-02-14 A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine Albayrak, Yakup Beyazyüz, Murat Abbak, Özlem Altındağ, Ece Clin Psychopharmacol Neurosci Case Report Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin reuptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders. Korean College of Neuropsychopharmacology 2019-02 2019-02-28 /pmc/articles/PMC6361034/ /pubmed/30690950 http://dx.doi.org/10.9758/cpn.2019.17.1.134 Text en Copyright © 2019, Korean College of Neuropsychopharmacology This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Albayrak, Yakup
Beyazyüz, Murat
Abbak, Özlem
Altındağ, Ece
A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
title A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
title_full A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
title_fullStr A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
title_full_unstemmed A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
title_short A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
title_sort report of rabbit syndrome who benefited from sigma 1 agonist fluvoxamine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361034/
https://www.ncbi.nlm.nih.gov/pubmed/30690950
http://dx.doi.org/10.9758/cpn.2019.17.1.134
work_keys_str_mv AT albayrakyakup areportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT beyazyuzmurat areportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT abbakozlem areportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT altındagece areportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT albayrakyakup reportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT beyazyuzmurat reportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT abbakozlem reportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine
AT altındagece reportofrabbitsyndromewhobenefitedfromsigma1agonistfluvoxamine

Ejemplares similares